DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD. et al.
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
J Clin Oncol 2010;
28: 3570-6
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.